title: Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo.
abstract: The phenylpteridine derivative BIBW22BS (BIBW22) is a potent modulator of multidrug resistance (MDR). We investigated BIBW22 in comparison to dexniguldipine and verapamil as modifier of MDR in blasts of de novo, relapsed or persistent acute myeloid leukemia (AML) in vitro. All patients with relapsed or persistent AML had been pretreated with idarubicin and cytosine arabinoside. The degree of MDR was determined by efflux kinetics of rhodamine 123 (R123), daunorubicin, and idarubicin measured by flow cytometry (FACS). A total of 51 patients with AML, 25 de novo and 26 relapsed or persistent, were investigated. While only 6 out of 25 de novo AML blast populations showed moderate efflux of R123 and daunorubicin, 17 out of 26 blast populations of relapsed or persistent AML had an efflux between 20% and 44% within 15 min ex vivo. This efflux could be significantly inhibited by 1 microM BIBW22, 1 microM dexniguldipine, or 10 microM verapamil. For idarubicin we found an effusion of 40+/-9% within 15 min in all blast populations that could not be inhibited by the modulators. Clinically achievable drug concentrations causing only moderate side-effects are in the range of 0.5 microM dexniguldipine and 3 microM verapamil. Up to now, BIBW22 has not been investigated clinically. Thus the potential toxicity of concentrations of 0.5-1 microM BIBW22, sufficient for an optimal efflux inhibition ex vivo, is not known yet. We conclude from our ex vivo investigations in blast populations of de novo, relapsed or persistent AML that BIBW22 is a potent modulator of MDR.
authors.affiliation: Innere Klinic and Poliklinik, Westdeutsches Tumorzentrum, Universitatsklinikum Essen, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Schröder
authors.forename: M
authors.initials: M
authors.lastname: Esteban
authors.forename: M R
authors.initials: MR
authors.lastname: Müller
authors.forename: S
authors.initials: S
authors.lastname: Kasimir-Bauer
authors.forename: U
authors.initials: U
authors.lastname: Bamberger
authors.forename: A
authors.initials: A
authors.lastname: Heckel
authors.forename: S
authors.initials: S
authors.lastname: Seeber
authors.forename: M E
authors.initials: ME
authors.lastname: Scheulen
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis; D003630:Daunorubicin / Q000493:pharmacokinetics; D018432:Drug Resistance, Multiple; D006801:Humans; D015255:Idarubicin / Q000493:pharmacokinetics; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009025:Morpholines / Q000494:pharmacology*; D020112:Rhodamine 123; D012235:Rhodamines / Q000493:pharmacokinetics; D014223:Triamterene / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D018952:Antigens, CD34; D009025:Morpholines; D012235:Rhodamines; C080982:BIBW 22; D020112:Rhodamine 123; D014223:Triamterene; D015255:Idarubicin; D003630:Daunorubicin